Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of EDP-305 in NASH
2017-004365-27Phase 2Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of EDP-305 in metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD) (3 arms), sponsored by Enanta Pharmaceuticals. Primary endpoint: Change from baseline in ALT levels at Week 12. Started Jul 2018; status: completed.
02
Drugs
EDP-305
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on 2017-004365-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004365-27.